ArticleBlood advances2020
Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy.JCO oncology practice · 2026Article
- A Deep Learning Model for IMMP-Based Residual Disease Monitoring in AML with Monocytic Differentiation.Diagnostics (Basel, Switzerland) · 2026Article
- Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings.Advances in hematology · 2026Review
- Examining inpatient chemotherapy utilization among patients with cancer and impact on outcomes.The oncologist · 2025Article
- Shared-Care in Complex Malignant Hematology: An Integrative Review Using the RE-AIM Evaluation Framework.Current oncology (Toronto, Ont.) · 2024Review
- Understanding the Extent of Polypharmacy and its Association With Health Service Utilization Among Persons With Cancer and Multimorbidity: A Population-Based Retrospective Cohort Study in Ontario, Canada.Journal of pharmacy practice · 2024Article
- Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy.Frontiers in oncology · 2024Review
- Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens.Haematologica · 2023Article
- A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care.HemaSphere · 2023Article
- Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia.Frontiers in oncology · 2023Article
- Rapid Response Team Activations in Oncologic Ambulatory Sites: Characteristics, Interventions, and Outcomes.JCO oncology practice · 2022Article
- Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma.Clinical hematology international · 2022Article
- Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.European journal of haematology · 2022Article
- Article
- Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation.JCO global oncology · 2021Review
- Treatment of Acute Leukemia During COVID-19: Focused Review of Evidence.Clinical lymphoma, myeloma & leukemia · 2021Review
- What Does the Economic Burden of Acute Myeloid Leukemia Treatment Look Like for the Next Decade? An Analysis of Key Findings, Challenges and Recommendations.Journal of blood medicine · 2021Review
- Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings.Hematology. American Society of Hematology. Education Program · 2020Review
- Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.JCO oncology practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
To improve patient quality of life and reduce health care costs, many conditions formerly thought to require inpatient care are now treated in the outpatient setting. Outpatient induction chemotherapy for acute myeloid leukemia (AML) may confer similar benefits. This possibility prompted a pilot study to explore the safety and feasibility of intensive outpatient initial or salvage induction chemotherapy administration for adults with AML and high-risk myelodysplastic syndrome (MDS). Patients with no significant organ dysfunction and a treatment-related mortality (TRM) score corresponding to a day 28 mortality rate of <5% to 10% were eligible for study. Patients were treated as outpatients with daily evaluation by providers and only admitted to the hospital if mandated by complications. Twenty patients were consented, and 17 were treated. Eight patients received initial induction chemotherapy and 9 received salvage induction chemotherapy. Fourteen patients completed induction chemotherapy administration in the outpatient setting (82.4%; exact 95% confidence interval [CI], 55.8-95.3). Three patients were admitted during the course of chemotherapy administration, 2 for neutropenic fever and 1 for grade 3 mucositis. No patients died within 14 days of the initiation of induction chemotherapy (exact 95% CI, 0-22.9). Results of this pilot study suggest it is feasible to complete outpatient induction chemotherapy in select patients with AML and high-risk MDS. A team including nurses, social workers, medical providers, and pharmacists was key to the successful implementation of outpatient induction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.